TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26448482
Drug: Parental concerns
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental concerns about treatment efficacy and side effects
Study: 21359598
Drug: Ezetimibe monotherapy
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe monotherapy 10 mg/day (EZT group)
Study: 16860035
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy with human recombinant alpha‐L‐iduronidase
Study: 10844053
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg daily) and nicotinamide (300 mg daily) for 3 months
Study: 9093632
Drug: Chloroquine-Chlorpheniramine combination
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine-Chlorpheniramine combination
Study: 3545785
Drug: Tetrabamate (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabamate (three 300 mg tablets/day)
Study: 21255807
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid 600 mg via intravenous infusion once a day for 3 weeks
Study: 29931320
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 20 mg/d
Study: 29931320
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 40 mg/d
Study: 29931320
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 60 mg/d
Study: 25081808
Drug: Daily weight
Normalized name: Thrifty White One Daily Weight Control Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily weight tracking
Study: 25081808
Drug: Weekly weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly weight tracking
Study: 18475028
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 1% ropivacaine and general anesthesia (epidural and general group, n=12)
Study: 18475028
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of saline and general anesthesia (general group, n=12)
Study: 11326160
Drug: Cefotiam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (1 g) and Metronidazole (0.5 g) intravenously 30 min before surgery
Study: 11326160
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g) intravenously 30 min before surgery
Study: 8781317
Drug: Steroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids plus interferon
Study: 1731672
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution (0.5%) irrigation
Study: 26850805
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of pomegranate extract daily for 30 days
Study: 25628416
Drug: Indapamide SR/Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide SR/Amlodipine (Amlodipine 10 mg subgroup)
Study: 25628416
Drug: Enalapril/Amlodipine (Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/Amlodipine (Amlodipine 10 mg subgroup)
Study: 24124708
Drug: Low-dose rFVIIa
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rFVIIa (20 µg/kg)
Study: 21905967
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg plus Amlodipine 10 mg
Study: 21905967
Drug: Telmisartan 40-80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40-80 mg plus Amlodipine 10 mg
Study: 17588688
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 gr/d)
Study: 15454860
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of nicorandil (1.0 microg.kg(‐1).min(‐1))
Study: 11207038
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Cisplatin 20 mg/m(2) i.v. per day for 4 days, followed by Cy 2 g/m(2) i.v. on day 4; 12 partial responses (PR), 1 mixed response, 3 stable disease (SD).
Study: 11207038
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Basic chemotherapy plus VP16 (50 mg/m(2) i.v. for 3 days) and Vincristine (1.5 mg/m(2) i.v. on days 1 and 6); 2 PR, 1 complete response (CR), and 2 very good partial responses (VGPR) in 5 patients treated at diagnosis.
Study: 11207038
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CO-TH) with 131-I-MIBG (200 mCi) administered on day 10 after chemotherapy; no extra-medullary toxicity observed, mild myelosuppression in patients treated at diagnosis.
Study: 9398455
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg triazolam (oral)
Study: 7991476
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (tissue plasminogen activator combined with intravenous heparin)
Study: 7991476
Drug: Accelerated administration
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated administration of tissue plasminogen activator (Activase) combined with intravenous heparin
Study: 3283460
Drug: HIGH arterial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH arterial lactate concentrations (perioperative infusion of Ringer's lactate)
Study: 22101205
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus cognitive behavioural therapy (CBT)
Study: 8696720
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and etoposide combination therapy
Study: 2071959
Drug: CPR 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR 0.5 g (0.5 g twice a day for 14 days)
Study: 2071959
Drug: CPR 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR 1.0 g (1.0 g twice a day for 14 days)
Study: 2071959
Drug: CAZ (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAZ (1.0 g twice a day for 14 days)
Study: 2071959
Drug: CPR 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR 0.5 g (in patients with pneumonia)
Study: 2071959
Drug: CPR 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR 1.0 g (in patients with pneumonia)
Study: 2071959
Drug: CPR 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR 0.5 g (in patients with chronic respiratory tract infection)
Study: 2071959
Drug: CPR 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR 1.0 g (in patients with chronic respiratory tract infection)
Study: 6140494
Drug: Concurrent internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent internal sepsis
Study: 31208475
Drug: Butter, cheese,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter, cheese, whipped cream, sour cream
Study: 19695922
Drug: Sodium glycididazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium glycididazole (700 mg/m² intravenous infusion 30 minutes before radiotherapy three times a week)
Study: 1669033
Drug: CMI +
Normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMI + LT3 (clomipramine 150 mg/day + LT3 50 micrograms/day)
Study: 1669033
Drug: CMI +
Normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMI + placebo (clomipramine 150 mg/day)
Study: 6365008
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches (10 mg) three times a day
Study: 26762528
Drug: Varicella vaccine
Normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicella vaccine without human serum albumin (HSA)
Study: 26762528
Drug: Licensed varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed varicella vaccine containing HSA
Study: 22332671
Drug: Control area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control area (chemical keratolytic treatment)
Study: 20382963
Drug: Treatment centre
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment centre
Study: 22379913
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Lornoxicam
Study: 16046230
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide suspension
Study: 9510982
Drug: Josacine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josacine 500 mg tablets (2 tablets)
Study: 9510982
Drug: Josamycin solution
Normalized name: josamycin
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin solution (1 g drug, buffered at pH 4.0)
Study: 7985598
Drug: Nadolol therapy
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol therapy
Study: 2686453
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptives
Study: 30533392
Drug: On-table extubation
Normalized name: Table sugar
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-table extubation (OTE) group with sufentanil 0.15 µg/kg/h
Study: 30533392
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with sufentanil 0.7-0.8 µg/kg/h
Study: 20885970
Drug: Secnidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole (2 g, once)
Study: 20885970
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg, b.i.d for seven days)
Study: 18978097
Drug: Diaphragm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm and lubricant gel provision
Study: 8871834
Drug: OH-chloroquine (OH-C)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OH-chloroquine (OH-C) 6 mg/kg/daily
Study: 6144316
Drug: Pancuronium (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 42 min)
Study: 6144316
Drug: Vecuronium (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 12 min)
Study: 6144316
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vecuronium (loading dose 0.075 mg kg‐1, continuous infusion 0.075 mg kg‐1 h‐1)
Study: 25113425
Drug: Left nostril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left nostril (Group L; n = 95)
Study: 18031501
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream and 1% hydrocortisone cream
Study: 15990738
Drug: High-dose glucose-insulin-potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucose-insulin-potassium (GIK) infusion
Study: 12469639
Drug: Intravesical immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical immunotherapy with imuron (6-week course) and maintenance therapy (3 weekly instillations each 3 months for the first year followed by once in 6 months)
Study: 12469639
Drug: Single monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single monthly instillations
Study: 12469639
Drug: Intravesical BCG-therapy
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG-therapy
Study: 7614099
Drug: Olsalazine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 0.5 g daily
Study: 7614099
Drug: Olsalazine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 1.25 g daily
Study: 7614099
Drug: Olsalazine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 2.0 g daily
Study: 7614099
Drug: Sulphasalazine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine 2.0 g daily
Study: 7614099
Drug: Olsalazine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (all doses)
Study: 2615532
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nystatin (NYS), pipemidic acid (PPA), and colistin sodium methanesulfonate (CLM)
Study: 21320227
Drug: Prescription group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription group (standard prescription)
Study: 19961726
Drug: Admission blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission blood glucose < 6.1 mmol/L
Study: 19961726
Drug: Admission blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission blood glucose 6.1 to 7.7 mmol/L
Study: 19961726
Drug: Admission blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission blood glucose > 13.0 mmol/L
Study: 19961726
Drug: Admission blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission blood glucose < 6.1 mmol/L in known diabetes
Study: 19961726
Drug: Admission blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission blood glucose 6.1 to 7.7 mmol/L in known diabetes
Study: 19961726
Drug: Admission blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission blood glucose > 13.0 mmol/L in known diabetes
Study: 15014355
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 500/600 mg/m + folinic acid with or without trimetrexate
Study: 11123736
Drug: Intermittent IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent IT morphine (5 microg x kg(‐1) four times a day)
Study: 11123736
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bupivacaine (40 microg x kg(‐1) x h(‐1)) and morphine (0.6 microg x kg(‐1) x h(‐1))
Study: 9298054
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide hydrochloride
Study: 30328767
Drug: Neuropsychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological treatment (control condition)
Study: 26703917
Drug: Zofenopril +
Normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril + Hydrochlorothiazide (Z + H) 30 + 12.5 mg
Study: 26703917
Drug: Irbesartan +
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan + Hydrochlorothiazide (I + H) 150 + 12.5 mg
Study: 23117779
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 or 5 mg/d)
Study: 23117779
Drug: Prasugrel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (5 mg/d for specific populations)
Study: 23117779
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d for specific populations)
Study: 23117779
Drug: Prasugrel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (5 mg/d for older participants)
Study: 23117779
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d for older participants)
Study: 20122047
Drug: Interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy (IPT) for minor depression
Study: 16224053
Drug: Atorvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 80 mg qd for 6 months
Study: 16224053
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg qd for 6 months
Study: 16337518
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide (45 mg)
Study: 1330318
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg sumatriptan
Study: 1330318
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg sumatriptan
Study: 1330318
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg sumatriptan (open-label for partial or non-responders)
Study: 3554658
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (250 mg/m2) given twice daily
Study: 3554658
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg)
Study: 2853038
Drug: Melatonin 100
Normalized name: melatonin 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 100 mg
Study: 23553447
Drug: Web-based questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based questionnaire for reporting adverse drug events (ADEs)
Study: 21701406
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (10-day regimen: omeprazole with amoxicillin for 5 days, followed by omeprazole, clarithromycin, and metronidazole for 5 days)
Study: 21701406
Drug: Tailored triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored triple therapy (7-day regimen: omeprazole with amoxicillin and clarithromycin for CLA-susceptible strains or metronidazole for CLA-resistant strains)
Study: 21701406
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment in CLA- and MET-susceptible strains
Study: 21701406
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment in CLA-resistant strains
Study: 12690904
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 g orally)
Study: 11164440
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae IgG antibodies
Study: 11164440
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae IgA antibodies
Study: 11164440
Drug: C. pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae antibody titres
Study: 1589246
Drug: Nalbuphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.2 mg/kg)
Study: 1589246
Drug: Aspirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (10 mg/kg)
Study: 3707649
Drug: Dopamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine at increasing doses of 2, 4, and 6 micrograms/kg/min
Study: 3707649
Drug: Ibopamine 50
Normalized name: ibopamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 50 mg (on day 1), 100 mg (on day 2), and dopamine (on day 3)
Study: 24447651
Drug: 16 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/kg sugammadex
Study: 24447651
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro (200 μg/mL sugammadex)
Study: 20078487
Drug: Tiapride (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (800 mg/day)
Study: 20078487
Drug: Lorazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (10 mg/day)
Study: 10613304
Drug: CTRx (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRx (5 Gy equivalent per fraction, 3-5 weekly fractions) with iodinated x-ray contrast media for dose enhancement
Study: 7485697
Drug: 2.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micrograms of recombinant HB vaccine given at birth, two, and six months of age (group A)
Study: 7485697
Drug: 2.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micrograms of recombinant HB vaccine given at two, four, and nine months of age (group B)
Study: 7485697
Drug: Routine childhood
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine childhood vaccines (BCG, DPT, polio, and measles) given to all groups
Study: 29315462
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of oral aprepitant
Study: 29315462
Drug: Oral starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral starch (control group)
Study: 26899608
Drug: DEX administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX administration (uni-DEX and bilateral-DEX groups)
Study: 26899608
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration (uni-saline group)
Study: 23039397
Drug: Sequential (SEQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential (SEQ) breast expression
Study: 17705848
Drug: Lubeck Reaction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeck Reaction Perimeter treatment, administered twice weekly for an average of 8.2 months, each session lasting 45 minutes.
Study: 17705848
Drug: Monocular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocular treatment conditions
Study: 12718823
Drug: Clinical evaluation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical evaluation and treatment for CAP
Study: 9581666
Drug: Isradipine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0, 5, and 10 mg)
Study: 9581666
Drug: Ethanol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0, 0.5, and 1 g/kg)
Study: 31705332
Drug: Introduction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Introduction of prescription drug co-payments (€0.50 to €2.50) for medical cardholders